Arcus Biosciences, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Arcus Biosciences, Inc. (RCUS) and UnitedHealth Group Incorporated (UNH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
UnitedHealth Group Incorporated scores ahead of Arcus Biosciences, Inc. on Q·Score (6.1 vs 5.1 out of 10), led by Quality (5.9 vs 0.2) and Sentiment (8.1 vs 7.3). Arcus Biosciences, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for RCUS (+47.1%) than for UNH (+2.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-156% margin).
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
Fundamentals
Frequently Asked Questions
RCUS vs UNH: which stock scores better overall?
Based on Q·Score, UnitedHealth Group Incorporated (UNH) scores 6.1/10 versus Arcus Biosciences, Inc. (RCUS) at 5.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: RCUS or UNH?
UnitedHealth Group Incorporated (UNH) scores higher on Growth (5.1/10 vs 4.5/10). Arcus Biosciences, Inc. reports revenue growth (-39.3% YoY) while UnitedHealth Group Incorporated reports (2.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is RCUS or UNH more attractively valued?
UnitedHealth Group Incorporated (UNH) scores higher on Valuation (6.5/10 vs 6/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about RCUS vs UNH?
There are 12 analysts covering RCUS with a consensus price target of $35.75, and 26 analysts covering UNH with a consensus target of $409.77. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: RCUS or UNH?
UnitedHealth Group Incorporated (UNH) scores higher on Quality (5.9/10 vs 0.2/10). Net profit margin: RCUS at -156.4%, UNH at 2.7%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: RCUS or UNH?
Arcus Biosciences, Inc. (RCUS) scores higher on Financial Health (9.2/10 vs 5.3/10). Market beta: RCUS at 0.84, UNH at 0.65. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of RCUS and UNH?
Arcus Biosciences, Inc. (RCUS) has a market capitalisation of $3.1B, while UnitedHealth Group Incorporated (UNH) has a market cap of $364.1B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →